ImmuPharma plc (LON:IMM – Get Free Report) was down 14.6% during trading on Wednesday . The company traded as low as GBX 3.20 ($0.04) and last traded at GBX 3.20 ($0.04). Approximately 13,200,714 shares were traded during mid-day trading, a decline of 53% from the average daily volume of 28,314,303 shares. The stock had previously closed at GBX 3.75 ($0.05).
ImmuPharma Stock Performance
The business’s 50 day moving average price is GBX 1.48 and its 200-day moving average price is GBX 1.66. The company has a market cap of £12.44 million, a price-to-earnings ratio of -298.80 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- Investing in Commodities: What Are They? How to Invest in Them
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- Stock Sentiment Analysis: How it Works
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- P/E Ratio Calculation: How to Assess Stocks
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
